These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35963986)

  • 1. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
    Ono T; Hino M; Matsumura I; Fujisawa S; Ishizawa K; Sakaida E; Sekiguchi N; Ono C; Aizawa M; Tanetsugu Y; Koide Y; Takahashi N
    Int J Hematol; 2022 Dec; 116(6):871-882. PubMed ID: 35963986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Hino M; Matsumura I; Fujisawa S; Ishizawa K; Ono T; Sakaida E; Sekiguchi N; Tanetsugu Y; Fukuhara K; Ohkura M; Koide Y; Takahashi N
    Int J Hematol; 2020 Jul; 112(1):24-32. PubMed ID: 32279228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Garrett M; Knight B; Cortes JE; Deininger MW
    Cancer Med; 2023 Sep; 12(17):17981-17992. PubMed ID: 37553873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
    Brümmendorf TH; Cortes JE; Milojkovic D; Gambacorti-Passerini C; Clark RE; le Coutre P; Garcia-Gutierrez V; Chuah C; Kota V; Lipton JH; Rousselot P; Mauro MJ; Hochhaus A; Hurtado Monroy R; Leip E; Purcell S; Yver A; Viqueira A; Deininger MW;
    Leukemia; 2022 Jul; 36(7):1825-1833. PubMed ID: 35643868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
    Takahashi N; Cortes JE; Sakaida E; Ishizawa K; Ono T; Doki N; Matsumura I; García-Gutiérrez V; Rosti G; Ono C; Ohkura M; Tanetsugu Y; Viqueira A; Brümmendorf TH
    Int J Hematol; 2022 Jun; 115(6):838-851. PubMed ID: 35235189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
    Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH
    Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
    Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
    Gambacorti-Passerini C; Cortes JE; Lipton JH; Dmoszynska A; Wong RS; Rossiev V; Pavlov D; Gogat Marchant K; Duvillié L; Khattry N; Kantarjian HM; Brümmendorf TH
    Am J Hematol; 2014 Oct; 89(10):947-53. PubMed ID: 24944159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
    Gambacorti-Passerini C; Cortes JE; Lipton JH; Kantarjian HM; Kim DW; Schafhausen P; Crescenzo R; Bardy-Bouxin N; Shapiro M; Noonan K; Leip E; DeAnnuntis L; Brümmendorf TH; Khoury HJ
    Haematologica; 2018 Aug; 103(8):1298-1307. PubMed ID: 29773593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
    Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Crescenzo R; Mamolo C; Reisman A; Hochhaus A; Brümmendorf TH;
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1589-1599. PubMed ID: 30989330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
    Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
    Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.
    Rosti G; Brümmendorf TH; Gjertsen BT; Giraldo-Castellano P; Castagnetti F; Gambacorti-Passerini C; Ernst T; Zhao H; Kuttschreuter L; Purcell S; Giles FJ; Hochhaus A
    Leukemia; 2024 Jan; 38(1):126-135. PubMed ID: 38007586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
    Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
    Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
    Hochhaus A; Gambacorti-Passerini C; Abboud C; Gjertsen BT; Brümmendorf TH; Smith BD; Ernst T; Giraldo-Castellano P; Olsson-Strömberg U; Saussele S; Bardy-Bouxin N; Viqueira A; Leip E; Russell-Smith TA; Leone J; Rosti G; Watts J; Giles FJ;
    Leukemia; 2020 Aug; 34(8):2125-2137. PubMed ID: 32572189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
    Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE
    Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
    Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
    Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
    Cortes JE; Kantarjian HM; Mauro MJ; An F; Nick S; Leip E; Gambacorti-Passerini C; Brümmendorf TH
    Eur J Haematol; 2021 Jun; 106(6):808-820. PubMed ID: 33638218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
    Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
    Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
    Yu W; Du X; Wang W; Lou J; Liu P; Meng L; Jin J
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e867-e873. PubMed ID: 35842355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.